Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease

By D. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, Caryn Vadseth, D. Choi, H. Ischiropoulos, S. Przedborski. Journal of Neuroscience, 2002

1,205 citations recorded by the source corpus.

Subfields: Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/8381205b0c47ad9056605c3aa40509c5da8f1d21

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

Citations in the corpus

Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation (2005, background): “Moreover, injury-induced increases in microglial CD11b mRNA expression were reduced by minocycline treatment (Raghavendra et al., 2003; Wu et al., 2002), whereas astrocytic GFAP mRNA expression was not different compared to vehicle-treated animals (Wu et al.”
Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy (2015, background): “Antioxidants can inhibit inflammatory responses and protect dopaminergic neurons as reported in laboratory and animal models of PD [78-84].”
Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease (2006, background): “This is critical finding to understand microgliosis in PD, as previous studies have identified that NADPHO-mediated microglial superoxide production is a mandatory microglial component to contribute MPP+ and MPTP induced dopamine toxicity both in vivo and in vitro (Wu et al., 2002; Gao et al., 2003)”
Inflammation after Intracerebral Hemorrhage (2007, background): “…examples of treatments that target microglial activation are the tetracycline derivatives minocycline and doxycycline, broad-spectrum antibiotics that have anti-inflammatory effects independent of their antimicrobial activity (Van Den Bosch et al, 2002; Wu et al, 2002a; Yrjanheikki et al, 1998).”
Inhibition of Microglial Activation Attenuates the Development but Not Existing Hypersensitivity in a Rat Model of Neuropathy (2003, background): “…by inhibiting microglial activation under various pathological conditions without affecting neurons, astroglia, or oligodendroglial progenitors (Amin et al., 1996; Yrjanheikki et al., 1998; Du et al., 2001; Tikka and Koistinaho, 2001; Tikka et al., 2001a,b; Wu et al., 2002; Zhang et al., 2003).”
Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention (2003, background): “For example, mice lacking inducible nitric oxide synthase activity are resistant to MPTP-induced lesions and inhibition of microglial activation reduces MPTP neurotoxicity (Itzhak et al., 1999; Liberatore et al., 1999; Dehmer et al., 2000; Du et al., 2001; Wu et al., 2002).”
Microglia and neurodegeneration: The role of systemic inflammation (2013, background): “Each of these enzymes have been described in both PD patients and models and preclinical studies have described a role for all three in toxicity to TH-positive cells of the substantia nigra (Choi et al., 2005; Hunot et al., 1996; Wu et al., 2002).”
Pathophysiology and pharmacologic treatment of acute spinal cord injury. (2004, background): “Minocycline, a tetracycline antibiotic, has been shown to inhibit excitotoxicity [123] and provide neuroprotection in models of Parkinson disease [124], autoimmune encephalomyelitis [125], amyotrophic lateral sclerosis [126] and adult and neonatal brain ischemia [125,127,128], most likely through it”